Angiogenesis in rheumatoid arthritis

Z. Szekanecz, Timea Besenyei, G. Paragh, Alisa E. Koch

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Angiogenesis is the formation of new capillaries from pre-existing vessels. A number of soluble and cell-bound factors may stimulate neovascularization. The perpetuation of angiogenesis involving numerous soluble and cell surface-bound mediators has been associated with rheumatoid arthritis (RA). These angiogenic mediators, among others, include growth factors, primarily vascular endothelial growth factor (VEGF) and hypoxia-inducible factors (HIFs), as well as pro-inflammatory cytokines, various chemokines, matrix components, cell adhesion molecules, proteases and others. Among the several potential angiogenesis inhibitors, targeting of VEGF, HIF-1, angiogenic chemokines, tumor necrosis factor-α and the αVβ3 integrin may attenuate the action of angiogenic mediators and thus synovial angiogenesis. In addition, some naturally produced or synthetic compounds including angiostatin, endostatin, paclitaxel, fumagillin analogues, 2-methoxyestradiol and thalidomide may be included in the management of RA.

Original languageEnglish
Pages (from-to)563-573
Number of pages11
JournalAutoimmunity
Volume42
Issue number7
DOIs
Publication statusPublished - 2009

Fingerprint

Chemokines
Vascular Endothelial Growth Factor A
Rheumatoid Arthritis
Angiostatins
Endostatins
Hypoxia-Inducible Factor 1
Thalidomide
Angiogenesis Inhibitors
Cell Adhesion Molecules
Paclitaxel
Integrins
Intercellular Signaling Peptides and Proteins
Peptide Hydrolases
Tumor Necrosis Factor-alpha
Cell Count
Cytokines
fumagillin
Hypoxia
2-methoxyestradiol

Keywords

  • Angiogenesis
  • Angiostasis therapy
  • Rheumatoid arthritis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Angiogenesis in rheumatoid arthritis. / Szekanecz, Z.; Besenyei, Timea; Paragh, G.; Koch, Alisa E.

In: Autoimmunity, Vol. 42, No. 7, 2009, p. 563-573.

Research output: Contribution to journalArticle

Szekanecz, Z. ; Besenyei, Timea ; Paragh, G. ; Koch, Alisa E. / Angiogenesis in rheumatoid arthritis. In: Autoimmunity. 2009 ; Vol. 42, No. 7. pp. 563-573.
@article{aa2ed0c341874f00b24be48f15982598,
title = "Angiogenesis in rheumatoid arthritis",
abstract = "Angiogenesis is the formation of new capillaries from pre-existing vessels. A number of soluble and cell-bound factors may stimulate neovascularization. The perpetuation of angiogenesis involving numerous soluble and cell surface-bound mediators has been associated with rheumatoid arthritis (RA). These angiogenic mediators, among others, include growth factors, primarily vascular endothelial growth factor (VEGF) and hypoxia-inducible factors (HIFs), as well as pro-inflammatory cytokines, various chemokines, matrix components, cell adhesion molecules, proteases and others. Among the several potential angiogenesis inhibitors, targeting of VEGF, HIF-1, angiogenic chemokines, tumor necrosis factor-α and the αVβ3 integrin may attenuate the action of angiogenic mediators and thus synovial angiogenesis. In addition, some naturally produced or synthetic compounds including angiostatin, endostatin, paclitaxel, fumagillin analogues, 2-methoxyestradiol and thalidomide may be included in the management of RA.",
keywords = "Angiogenesis, Angiostasis therapy, Rheumatoid arthritis, Vascular endothelial growth factor",
author = "Z. Szekanecz and Timea Besenyei and G. Paragh and Koch, {Alisa E.}",
year = "2009",
doi = "10.1080/08916930903143083",
language = "English",
volume = "42",
pages = "563--573",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Angiogenesis in rheumatoid arthritis

AU - Szekanecz, Z.

AU - Besenyei, Timea

AU - Paragh, G.

AU - Koch, Alisa E.

PY - 2009

Y1 - 2009

N2 - Angiogenesis is the formation of new capillaries from pre-existing vessels. A number of soluble and cell-bound factors may stimulate neovascularization. The perpetuation of angiogenesis involving numerous soluble and cell surface-bound mediators has been associated with rheumatoid arthritis (RA). These angiogenic mediators, among others, include growth factors, primarily vascular endothelial growth factor (VEGF) and hypoxia-inducible factors (HIFs), as well as pro-inflammatory cytokines, various chemokines, matrix components, cell adhesion molecules, proteases and others. Among the several potential angiogenesis inhibitors, targeting of VEGF, HIF-1, angiogenic chemokines, tumor necrosis factor-α and the αVβ3 integrin may attenuate the action of angiogenic mediators and thus synovial angiogenesis. In addition, some naturally produced or synthetic compounds including angiostatin, endostatin, paclitaxel, fumagillin analogues, 2-methoxyestradiol and thalidomide may be included in the management of RA.

AB - Angiogenesis is the formation of new capillaries from pre-existing vessels. A number of soluble and cell-bound factors may stimulate neovascularization. The perpetuation of angiogenesis involving numerous soluble and cell surface-bound mediators has been associated with rheumatoid arthritis (RA). These angiogenic mediators, among others, include growth factors, primarily vascular endothelial growth factor (VEGF) and hypoxia-inducible factors (HIFs), as well as pro-inflammatory cytokines, various chemokines, matrix components, cell adhesion molecules, proteases and others. Among the several potential angiogenesis inhibitors, targeting of VEGF, HIF-1, angiogenic chemokines, tumor necrosis factor-α and the αVβ3 integrin may attenuate the action of angiogenic mediators and thus synovial angiogenesis. In addition, some naturally produced or synthetic compounds including angiostatin, endostatin, paclitaxel, fumagillin analogues, 2-methoxyestradiol and thalidomide may be included in the management of RA.

KW - Angiogenesis

KW - Angiostasis therapy

KW - Rheumatoid arthritis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=71049131072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049131072&partnerID=8YFLogxK

U2 - 10.1080/08916930903143083

DO - 10.1080/08916930903143083

M3 - Article

C2 - 19863375

AN - SCOPUS:71049131072

VL - 42

SP - 563

EP - 573

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 7

ER -